v3.25.4

Acquisitions - Narrative (Details) - USD ($) $ in Thousands |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
May 30, 2024 | Feb. 05, 2024 | Jun. 30, 2025 | Mar. 31, 2025 | Dec. 31, 2025 | Dec. 31, 2024 | Dec. 31, 2023
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Research and development |  |  |  |  | $ 2,050,152 | $ 2,606,848 | $ 1,627,594
Escient |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Payments for asset acquisitions | $ 782,500 |  |  |  |  |  |
Asset acquisition, consideration transferred, transaction cost | 2,500 |  |  |  |  |  |
Upfront payment | 785,000 |  |  |  |  |  |
Asset acquisition, compensation expense |  |  |  |  |  | 31,500 |
In-process research and development assets | 679,388 |  |  |  |  |  |
Research and development |  |  |  |  |  | $ 679,400 |
Escient | In Process Research and Development - INCB000262 |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
In-process research and development assets | 644,800 |  |  |  |  |  |
Escient | In Process Research and Development - INCB000547 |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
In-process research and development assets | $ 34,600 |  |  |  |  |  |
Xencor |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Payment to acquire license agreement |  |  |  | $ 12,500 |  |  |
Maximum | Xencor |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Uncured material breach, written notice period (in days) |  | 120 days |  |  |  |  |
Payment obligation breach, written notice period (in days) |  | 30 days |  |  |  |  |
Minimum | Xencor |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Advance written notice period (in days) |  | 90 days |  |  |  |  |
Regulatory Milestone | Xencor |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Milestone payment made under license agreement |  |  | $ 25,000 |  |  |  |
Milestone payment, estimated useful life |  |  | 8 years |  |  |  |
Development and Regulatory Milestones | Maximum | Xencor |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Additional milestone payments under the license agreement |  |  |  |  | 145,000 |  |
Commercialization Milestones | Maximum | Xencor |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Additional milestone payments under the license agreement |  |  |  |  | $ 50,000 |  |
Expiration period (in years) |  | 11 years |  |  |  |  |
MorphoSys AG |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Payment to acquire license agreement |  | $ 25,000 |  |  |  |  |

X
- Definition Asset Acquisition, Compensation Expense + References No definition available. + Details
Name: | incy_AssetAcquisitionCompensationExpense
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the additional milestone payments to be made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementAdditionalMilestonePayments
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License Agreement, Advance Written Notice Period + References No definition available. + Details
Name: | incy_LicenseAgreementAdvanceWrittenNoticePeriod
Namespace Prefix: | incy_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the amount of the milestone payment made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementMilestonePaymentAmountPaid
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License Agreement Milestone Payment, Useful Life + References No definition available. + Details
Name: | incy_LicenseAgreementMilestonePaymentUsefulLife
Namespace Prefix: | incy_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Royalty Obligation Expiration Period + References No definition available. + Details
Name: | incy_LicenseAgreementRoyaltyObligationExpirationPeriod
Namespace Prefix: | incy_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Written Notice Period For Payment Obligation Breach + References No definition available. + Details
Name: | incy_LicenseAgreementWrittenNoticePeriodForPaymentObligationBreach
Namespace Prefix: | incy_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition License Agreement, Written Notice Period For Uncured Material Breach + References No definition available. + Details
Name: | incy_LicenseAgreementWrittenNoticePeriodForUncuredMaterialBreach
Namespace Prefix: | incy_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Payments For Asset Acquisitions + References No definition available. + Details
Name: | incy_PaymentsForAssetAcquisitions
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments To Acquire License Agreement + References No definition available. + Details
Name: | incy_PaymentsToAcquireLicenseAgreement
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction cost incurred as part of consideration transferred in asset acquisition. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details
Name: | us-gaap_AssetAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details
Name: | us-gaap_IndefinitelivedIntangibleAssetsAcquired
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=incy_EscientPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=incy_InProcessResearchAndDevelopmentINCB000262Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=incy_InProcessResearchAndDevelopmentINCB000547Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=incy_XencorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=incy_MorphoSysAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |